65,437 trials
Anemia · Chronic Kidney Disease (CKD)
Primary: Mean Absolute Change in Hemoglobin Levels Between the Screening/Baseline Period (Week -4 to Day 1) and the Evaluation Period (Week 21-28) — -0.0960; -0.0035 g/dL
Renal Insufficiency, Chronic · Anemia · Renal Dialysis
Primary: Percentage of Hemoglobin Measurements Within 10 to 11 g/dL During the Evaluation Period — 46.41; 46.02 percentage of hemoglobin measurements — p=0.46
Breast Cancer · Mastectomy
Primary: Complication Rates — 4; 3 Participants
HIV Infections
Primary: Proportion of Sexual Exposures Covered by Pre- and Post-exposure Dosing — 75; 56; 52; 85 percentage of sexual exposures
Deep Vein Thrombosis · Venous Thrombosis
Primary: Relative Change From Baseline in Thrombus Volume Assessed by MRI [Using the Magnetic Resonance Venography (MRV) Method] — -46.6; -51.4 percentage of change
Facial Injuries · Adipose Tissue
Primary: Facial Volume Score — 1.8; 2.2; 2.2; 2.6 units on a scale
Peripheral Arterial Disease
Primary: Primary Safety Endpoint — 82.4; 82.4 percentage of subjects
Obesity
Primary: Mean Percent Total Body Weight Loss — 5.7 percentage of TBW
Lower Limb Spasticity Due to Cerebral Palsy
Primary: Change From Baseline in the Ashworth Scale (AS) Score of Plantar Flexors of the Primary Body Side at Day 29 (Week 4) of the First Injection Cycle (1st IC) — -0.7; -0.66…
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Primary: Part A Treatment Cohort: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 331; 177; 333; 176 participants
Autoimmune Connective Tissue Disorder · Immune System Diseases
Primary: Clinical Remission From Months 3-6 — 2 Participants
Depression
Primary: Montgomery Asberg Depression Rating Scale (MADRS) — 16.62 units on a scale
Bipolar Disorder · Anxiety Disorders
Primary: Reductions Over Time in Anxiety Symptoms as Measured by Hamilton Anxiety Rating Scale — 14; 18.81; 11.78; 17.70 Units on scale — p=.02
Diabetes
Primary: Number of Subjects With Numeric Meter Results When Users Obtain Fingerstick Capillary Blood Using the Styx Lancing Device ( 28 Gauge Lancets) — 119 participants
Graft Versus Host Disease
Primary: Number of Participants Experiencing Treatment Success — 8 Participants